Hvilken er prisen på Galmed Pharmaceuticals Ltd. (GLMD)

Prisen på Galmed Pharmaceuticals Ltd. (GLMD) er $0.5225

Hva er markedsverdien på Galmed Pharmaceuticals Ltd. (GLMD)

Markedsverdien på Galmed Pharmaceuticals Ltd. (GLMD) er $4.32M

Galmed Pharmaceuticals Ltd. (GLMD) P/B-forhold

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

År	P/B-forhold	Endre
Ikke nok data for de angitte datoene.

År

P/B-forhold

Endre

Ikke nok data for de angitte datoene.

Selskap	P/B-forhold	Forskjell i P/B-forhold	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	-	BE

Selskap

P/B-forhold

Forskjell i P/B-forhold

Land